OpenURL Connection Search

Select item for more details and to access through your institution.

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
Published in:
Infectious Diseases & Therapy, 2023, v. 12, n. 9, p. 2269, doi. 10.1007/s40121-023-00861-7
By:
- Hobbs, F. D. Richard;
- Montgomery, Hugh;
- Padilla, Francisco;
- Simón-Campos, Jesus Abraham;
- Kim, Kenneth;
- Arbetter, Douglas;
- Padilla, Kelly W.;
- Reddy, Venkatesh Pilla;
- Seegobin, Seth;
- Streicher, Katie;
- Templeton, Alison;
- Viani, Rolando M.;
- Johnsson, Eva;
- Koh, Gavin C. K. W.;
- Esser, Mark T.
Publication type:
Article
Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.
Published in:
International Journal of COPD, 2021, v. 16, p. 1637, doi. 10.2147/COPD.S309320
By:
- Fahy, William A;
- Homayoun-Valiani, Farshid;
- Cahn, Anthony;
- Robertson, Jon;
- Templeton, Alison;
- Meeraus, Wilhelmine H;
- Wilson, Robert;
- Lowings, Mike;
- Marotti, Miriam;
- West, Sarah L;
- Tabberer, Maggie;
- Hessel, Edith M
Publication type:
Article
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
Published in:
Clinical Infectious Diseases, 2023, v. 76, n. 7, p. 1247, doi. 10.1093/cid/ciac899
By:
- Levin, Myron J;
- Ustianowski, Andrew;
- Thomas, Steven;
- Templeton, Alison;
- Yuan, Yuan;
- Seegobin, Seth;
- Houlihan, Catherine F;
- Menendez-Perez, Ibrahim;
- Pollett, Simon;
- Arends, Rosalinda H;
- Beavon, Rohini;
- Dey, Kanika;
- Garbes, Pedro;
- Kelly, Elizabeth J;
- Koh, Gavin C K W;
- Ivanov, Stefan;
- Near, Karen A;
- Sharbaugh, Audrey;
- Streicher, Katie;
- Pangalos, Menelas N
Publication type:
Article
Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
Published in:
Journal of Infectious Diseases, 2023, v. 227, n. 10, p. 1153, doi. 10.1093/infdis/jiad014
By:
- Forte-Soto, Pablo;
- Albayaty, Muna;
- Brooks, Dennis;
- Arends, Rosalinda H;
- Tillinghast, John;
- Aksyuk, Anastasia A;
- Bouquet, Jerome;
- Chen, Cecil;
- Gebre, Asfiha;
- Kubiak, Robert J;
- Reddy, Venkatesh Pilla;
- Seegobin, Seth;
- Streicher, Katie;
- Templeton, Alison;
- Esser, Mark T
Publication type:
Article

Found: 4

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.

Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study.

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.